Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma
Authors:
- 10 September 2020
- journal article
- editorial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 126 (1) , 102-104
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Endotypes of severe allergic asthma patients who clinically benefit from anti‐IgE therapyClinical & Experimental Allergy, 2018
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Dupilumab in the management of moderate-to-severe asthma: the data so farTherapeutics and Clinical Risk Management, 2017
- Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safetyRespiratory Medicine, 2017
- The Efficacy and Safety of Antiinterleukin 13, a Monoclonal Antibody, in Adult Patients With AsthmaMedicine, 2016
- External validation of blood eosinophils, FENOand serum periostin as surrogates for sputum eosinophils in asthmaThorax, 2014
- The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophiliaEuropean Respiratory Journal, 2014
- Exploring the Effects of Omalizumab in Allergic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard TherapyAnnals of Internal Medicine, 2011
- Exhaled nitric oxide thresholds associated with a sputum eosinophil count >=3% in a cohort of unselected patients with asthmaThorax, 2010